Brokerages Set OrthoPediatrics Corp. (NASDAQ:KIDS) PT at $35.83

OrthoPediatrics Corp. (NASDAQ:KIDS) has received an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $35.83.

KIDS has been the topic of a number of analyst reports. Wall Street Zen upgraded OrthoPediatrics from a “sell” rating to a “hold” rating in a research report on Friday, June 27th. Needham & Company LLC reiterated a “buy” rating and set a $42.00 price objective on shares of OrthoPediatrics in a research report on Thursday, May 8th. Piper Sandler reduced their price objective on OrthoPediatrics from $40.00 to $30.00 and set an “overweight” rating on the stock in a research report on Thursday, May 8th. Stifel Nicolaus reduced their price objective on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, March 5th. Finally, Lake Street Capital initiated coverage on OrthoPediatrics in a research report on Monday, April 7th. They set a “buy” rating and a $37.00 price objective on the stock.

OrthoPediatrics Price Performance

Shares of OrthoPediatrics stock opened at $21.86 on Friday. The business has a 50 day simple moving average of $21.43 and a two-hundred day simple moving average of $23.07. OrthoPediatrics has a 12 month low of $19.52 and a 12 month high of $35.99. The stock has a market capitalization of $530.98 million, a P/E ratio of -12.49 and a beta of 1.10. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.19 and a quick ratio of 2.99.

OrthoPediatrics (NASDAQ:KIDS) last announced its earnings results on Wednesday, May 7th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.13). OrthoPediatrics had a negative net margin of 19.15% and a negative return on equity of 7.03%. The firm had revenue of $52.41 million for the quarter, compared to analyst estimates of $51.68 million. As a group, analysts predict that OrthoPediatrics will post -0.93 EPS for the current fiscal year.

Institutional Investors Weigh In On OrthoPediatrics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GAMMA Investing LLC increased its stake in OrthoPediatrics by 4,618.2% during the first quarter. GAMMA Investing LLC now owns 10,616 shares of the company’s stock worth $261,000 after acquiring an additional 10,391 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in OrthoPediatrics by 29.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company’s stock worth $15,576,000 after acquiring an additional 152,681 shares during the last quarter. SG Americas Securities LLC increased its stake in OrthoPediatrics by 175.0% during the first quarter. SG Americas Securities LLC now owns 20,039 shares of the company’s stock worth $494,000 after acquiring an additional 12,753 shares during the last quarter. JPMorgan Chase & Co. increased its stake in OrthoPediatrics by 204.8% during the fourth quarter. JPMorgan Chase & Co. now owns 42,817 shares of the company’s stock worth $992,000 after acquiring an additional 28,768 shares during the last quarter. Finally, HighTower Advisors LLC acquired a new stake in OrthoPediatrics during the fourth quarter worth $268,000. Institutional investors and hedge funds own 69.05% of the company’s stock.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.